In vitro Antioxidant, In vivo Bioavailability, and Immunomodulatory Effects of a Polyherbal Formulation (Storg B) Induced by Cyclophosphamide in an Experimental Animal Model
{"title":"In vitro Antioxidant, In vivo Bioavailability, and Immunomodulatory Effects of a Polyherbal Formulation (Storg B) Induced by Cyclophosphamide in an Experimental Animal Model","authors":"Firoz H M, Sadashiva C T, Sahana C V","doi":"10.9734/jpri/2024/v36i47508","DOIUrl":null,"url":null,"abstract":"Introduction: The immunomodulatory properties of plants are being extensively explored these days as they contain a wide range of bioactive compounds that can treat immunomodulatory disorders. The aim of the present investigation was to determine the efficacy of the standardized polyherbal formulation (Storg-B). The Storg-B combines Psidium guajava, Mangifera indica, and Citrus limon.\nMethods: The aqueous extract of the Storg B was investigated for DPPH radical scavenging activity to determine antioxidant activity. SD rats were selected for the evaluation of the immunomodulatory activity of Storg-B. The haemagglutination and hematology methods were used to evaluate the immunomodulatory studies. For the pharmacokinetic studies, the LC-MS/MS technique is employed to quantify Storg B.\nResults: The percentage inhibition of DPPH radial IC50 values of standard BHT and Storg-B were 60.52 and 68.35µg/ml, respectively. In the in vivo animal studies, Storg-B showed significant immunomodulatory activity by increasing the primary and secondary antibody titer values by 6.58 and 8.25 mg/mL, respectively, for the SRBC antigen at a dose of 100 mg/kg. There’s also an increase in the neutrophil adhesion percentage at the testing doses. Results of hematological parameters revealed that Storg-B restored all the levels of blood components at a 100 mg/kg dose. A Storg-B showed greater potency in the bioavailability studies.\nConclusion: Thus, the Storg-B used as an efficient and secure formulation in the treatment of immune deficiency by improving the immune response.","PeriodicalId":506675,"journal":{"name":"Journal of Pharmaceutical Research International","volume":"38 7","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmaceutical Research International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.9734/jpri/2024/v36i47508","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: The immunomodulatory properties of plants are being extensively explored these days as they contain a wide range of bioactive compounds that can treat immunomodulatory disorders. The aim of the present investigation was to determine the efficacy of the standardized polyherbal formulation (Storg-B). The Storg-B combines Psidium guajava, Mangifera indica, and Citrus limon.
Methods: The aqueous extract of the Storg B was investigated for DPPH radical scavenging activity to determine antioxidant activity. SD rats were selected for the evaluation of the immunomodulatory activity of Storg-B. The haemagglutination and hematology methods were used to evaluate the immunomodulatory studies. For the pharmacokinetic studies, the LC-MS/MS technique is employed to quantify Storg B.
Results: The percentage inhibition of DPPH radial IC50 values of standard BHT and Storg-B were 60.52 and 68.35µg/ml, respectively. In the in vivo animal studies, Storg-B showed significant immunomodulatory activity by increasing the primary and secondary antibody titer values by 6.58 and 8.25 mg/mL, respectively, for the SRBC antigen at a dose of 100 mg/kg. There’s also an increase in the neutrophil adhesion percentage at the testing doses. Results of hematological parameters revealed that Storg-B restored all the levels of blood components at a 100 mg/kg dose. A Storg-B showed greater potency in the bioavailability studies.
Conclusion: Thus, the Storg-B used as an efficient and secure formulation in the treatment of immune deficiency by improving the immune response.